RxDoctor Payments Data

Kenneth Pugar, DO

Neurology · Centerville, OHNPI 1528060399

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $445,383 of the $581,669 with a category attached, or 76.6%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 37.5% of the total. Among neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$581,669in general payments, 2019–2025

Across 1,508 payments — averaging $385.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$218K
  • Biogen$183K
  • Sanofi$58K
  • Eisai Inc.$38K
  • Lilly USA, LLC$31K
  • Avanir Pharmaceuticals, Inc.$26K
  • plus $27K from 54 others
$1,339,929in research payments, 2019–2025

Across 309 payments — averaging $4336.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$1M
  • Novartis$210K
  • Acadia Pharmaceuticals Inc$28K
  • MDD US Operations, LLC$24K
  • Biogen$17K
  • Eli Lilly$16K
  • plus $21K from 2 others

What the payments were for

  • Consulting fees$49,7639%
  • Speaking & faculty fees$445,38377%
  • Travel & lodging$54,4389%
  • Food & beverage$31,4985%
  • Education$5870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.235$218,259
Biogen190$183,485
Sanofi73$58,154
Eisai Inc.62$37,849
Lilly USA, LLC92$31,010
Avanir Pharmaceuticals, Inc.34$25,665
Acadia Pharmaceuticals Inc38$6,222
Genentech USA, Inc.25$5,036
AbbVie(2 entities)142$2,634
Novartis85$2,344
AstraZeneca(2 entities)41$1,173
Amgen(2 entities)46$1,155
MDD US Operations, LLC44$1,077
Teva Pharmaceuticals USA, Inc.56$984
UCB, Inc.39$755
Neurocrine Biosciences, Inc.33$491
Pfizer28$469
Biohaven Pharmaceutical Holding Company Ltd.20$459
Johnson & Johnson19$442
SK Life Science, Inc.21$375
Biohaven Pharmaceuticals, Inc.18$359
Amneal Pharmaceuticals LLC17$330
Acorda Therapeutics, Inc20$323
Sunovion Pharmaceuticals Inc.16$268
Lundbeck LLC9$166
TG Therapeutics, Inc.5$156
E.r. Squibb & Sons, L.L.C.3$148
Argenx US, Inc.6$144
Axsome Therapeutics, Inc.7$137
Abbott1$129
Supernus Pharmaceuticals, Inc.6$98
Jazz Pharmaceuticals Inc.5$96
CSL Behring7$96
Kyowa Kirin, Inc.4$94
Genentech, Inc.3$89
Amylyx Pharmaceuticals, Inc.5$84
Ipsen Biopharmaceuticals, Inc5$75
Grifols USA, LLC4$73
Otsuka America Pharmaceutical, Inc.3$73
Adamas Pharmaceuticals, Inc.5$71
Takeda Pharmaceuticals U.S.A., Inc.3$60
Merz Pharmaceuticals, LLC3$57
Bristol Myers Squibb3$51
Zyla Life Sciences, Inc.3$40
Vanda Pharmaceuticals Inc.1$39
Octapharma USA, Inc.2$39
Alnylam Pharmaceuticals Inc.2$34
Tanabe Pharma America, Inc.2$33
Harmony Biosciences LLC2$32
Catalyst Pharmaceuticals, Inc.1$27
Boston Scientific1$26
Vertical Pharmaceuticals, LLC2$24
Portola Pharmaceuticals, LLC2$24
Philips North America LLC1$22
Medtronic1$21
Neurelis, Inc.1$19
Cala Health, Inc.1$17
Merz North America, Inc.1$16
Corium, LLC1$13
Alfasigma USA, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581,669 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$194,728
Medicare patients
275
Services billed
3,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$233,861
NuedextaDextromethorphan Hbr/Quinidine11$19,009
Dalfampridine ErDalfampridine20$6,381
Rasagiline Mesylate11$1,327
Memantine Hcl73$1,112
Tizanidine Hcl35$956
Duloxetine Hcl49$900
Propranolol Hcl27$837
Donepezil Hcl124$808
Carbidopa-LevodopaCarbidopa/Levodopa63$742
Divalproex Sodium ErDivalproex Sodium11$635
Topiramate24$573
Primidone34$496
Gabapentin45$486
Propranolol Hcl ErPropranolol Hcl16$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$73$233,86116 claims
Avanir Pharmaceuticals, Inc.Nuedexta$25,665$19,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.

Other neurology in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →